Niemann-Pick disease, type C1 (NPC1) is a neurodegenerative disorder with limited treatment options. NPC1 is associated with neuroinflammation; however, attempts to therapeutically target neuroinflammation in NPC1 have had mixed success. We show here that NPC1 neuroinflammation is characterized by an atypical microglia activation phenotype. Specifically,
Introduction
Niemann-Pick disease, type C1 (NPC1) is a rare, neurodegenerative disorder characterized by progressive cerebellar ataxia and dementia (1) . Classically, NPC1 presents in childhood or early adolescence, but the phenotypic spectrum ranges from a severe neonatal form to an indolent adult-onset disorder (1, 2) . NPC is caused by mutations in either NPC1 or NPC2 (1). NPC1 functions to transport cholesterol out of the endolysosomal compartment and loss of NPC1 activity results in endolysosomal accumulation of unesterified cholesterol and lipids (3, 4) . Human NPC1 is recapitulated by the Npc1 nih (Npc1 increased storage of unesterified cholesterol and gangliosides (6) in the central nervous system (CNS) and liver, like NPC1 patients (3, 5) . Using the Npc1 À/À mouse model, multiple groups have attempted to treat NPC1 neurodegeneration using both candidate drugs (6) (7) (8) (9) and gene therapy (10, 11) . There are currently no FDA approved therapies for NPC1; however, miglustat (Zavesca) is approved for use in Europe and other countries (12) . Intrathecal 2-hydroxypropyl-b-cyclodextrin (HPbCD, VTS-270) has been shown in a phase 1/2a study to decrease neurological progression (13) and is currently being evaluated in an international phase 2b/3 trial. Chronic neuroinflammation and glial cell activation, as previously reported in NPC1 (14) , is often accompanied by accumulation of peripheral immune cells into the CNS. This process occurs in several other neurodegenerative diseases including amyotrophic lateral sclerosis (ALS) and Alzheimer disease (AD) as well as other lysosomal storage diseases (LSDs) such as Sandhoff and Batten disease (15) (16) (17) (18) . These recruited inflammatory cells exacerbate neuronal death and tissue damage through effects of secreted pro-inflammatory cytokines such as IL-6, IL1b and TNFa (15) . Inflammatory markers are significantly upregulated in NPC1 patients relative to controls, most notably the complement protein C3 and chemokine CCL3 (19, 20) . These same markers are also upregulated in the Npc1 nih mouse model (19, 20) . Targeting these inflammatory pathways, either through cell depletion or cytokine blocking, has been successfully used in several neurodegenerative disorders, including AD, ALS, NPC1 and Sandhoff disease (9, 18, (21) (22) (23) .
The immunological hallmark of most neurodegenerative diseases is microgliosis (24) . Chronic microglia activation is thought to contribute to the progression of common neurodegenerative diseases such ALS, AD and Parkinson disease (24, 25) . Microglial activation has been reported in several studies of NPC1 using both patient samples and murine models (14, 19, 26, 27) . Suzuki et al. (23) showed that heightened STAT1 activation in microglia contributed to neurotoxicity and crossing the Npc1 nih allele onto an IL-6-deficient background significantly increased the lifespan of NPC1 mice. These findings suggest a pathogenic role of inflammation in the NPC1. In contrast, based on genetic deletion of a series of immune mediators Ccl3, C1qa, C3, Mmp12, Bcl2l11, Tlr7 and Unc93b1 that are highly expressed in Npc1 mutant mice, Lopez et al. (19, 20) concluded that the inflammatory response in NPC1 is likely a secondary response rather than a primary component in the NPC1 pathological cascade. Cologna et al. (14) also observed that genetic deletion of Ccl3 did not ameliorate pathology in the Npc1 À/À mouse. Smith et al. (22) reported decreased brain CD68 staining and increased lifespan in mice treated with ibuprofen alone or in combination with miglustat, suggesting a benefit of targeting neuroinflammation. Thus, it is currently unclear to what degree microglia contribute to NPC1 disease progression and to what degree suppression of microglial activation may impact NPC1 pathology. Therefore, we sought to characterize neuroinflammation in detail and investigate the potential therapeutic benefit by modulating microglial activation in the NPC1 mouse model. 
Results

Peripheral immune cells do not
NPC1 expression in peripheral immune cells does not contribute to NPC1 pathology
Microglia are derived from the fetal yolk sac, migrate to the CNS and are radioresistant (30) . Thus, their contribution to disease pathology can be distinguished from that of radiosensitive peripheral monocytes/macrophages and other immune cells deriving from the bone marrow using bone marrow chimeric mice. To test whether radioresistant microglia or radiosensitive hematopoietic cells contribute to pathology in NPC1 mutant mice, we generated bone marrow chimeras and assessed disease progression (Supplementary Material, Fig. S2 ). We found that Npc1 þ/þ bone marrow does not rescue Npc1 À/À recipient animals. Specifically, we did not observe any differences in Npc1
mice. We also observed no change in motor activity, weight loss or survival in Npc1
þ/þ mice indicating that peripheral immune cells lacking NPC1 do not contribute to neuropathology. These data collectively show that peripheral inflammatory cells do not contribute to the morbidity and mortality in Npc1 À/À mice.
Therefore, therapies aimed at reducing neuroinflammation in NPC1 need to be targeted against CNS resident microglia.
Microglia morphology in Npc1
À/À mice correlates with disease progression
Upon activation microglia undergo a characteristic change in morphology from a ramified state to a rounded appearance with a decreased number and length of cellular processes (31) . We used flow cytometry ( Fig. 1A and Supplementary Material, Fig. S3 ) and fluorescence microscopy ( Fig. 1B-C) to analyze the morphology of microglia. Between 3 and 9 weeks of age we found changes in microglia morphology in Npc1 À/À mice ( Fig. 1A and B). With disease progression, the microglia became more rounded compared to the ramified morphology of Npc1 þ/þ mice consistent with a shift toward an activated and reactive state. Consistent with the observed morphological changes, microglia processes in Npc1 À/À mice were shorter (Fig. 1C ) and decreased in number (Fig. 1D ).
To test whether changes in microglia morphology were characteristic of LSDs in general, or specific to NPC1, we also analyzed microglia morphology in two other LSDs. Microglia from Mcoln1 À/À mice exhibited less dramatic changes in morphology compared to Npc1 À/À mice and, as anticipated, no significant morphological changes were observed in Gla À/À mice ( Fig. 1A-D) . These data suggest that a lysosomal storage defect alone is not sufficient to trigger a shift toward an amoeboid morphology in Npc1 À/À mice. ) mice. These latter two mutant mice are on a C57BL6 background whereas the NPC1 mice are on a BALB/C background. FACS analysis shows no changes in size and granularity compared to C57BL6 controls for ei-
IBA1 staining (green) in the cerebellum, thalamus and frontal cortex for Npc1 control and mutant mice at 3, 7 and 9 weeks of age showing a transition to a less ramified amoeboid morphology. Gla À/À and Mcoln1 À/À microglia at 4 months of age appear more ramified than the Npc1 mutant microglia.
Scale bar: 20 mm. Quantification of microglial cell projection length (C) and number (D).
Npc1
À/À microglia express decreased levels of microglia lineage markers
We next analyzed surface expression of activation and lineage markers of Npc1 þ/þ and Npc1 À/À microglia over the course of disease progression. Npc1 À/À microglia had significant reductions in the expression of the classical microglia markers CX 3 CR1 and CD11b first noted at 7 weeks of age ( Fig. 2A and Supplementary Material, Fig. S1 ), a time point consistent with the appearance of NPC1 symptoms. Expression of microglia activation markers MHCII, F4/80 and CD86 remained unchanged ( Fig. 2A) . In contrast to NPC1, microglia from Mcoln1 À/À mice had a minor decrease in CX 3 CR1 and increased CD86 and MHCII expression, while Gla À/À microglia were simi- Fig.   S1 ). Western blot analysis confirmed the decrease in CX 3 CR1 expression (Fig. 3A) . Biochemically, NPC1 is characterized by endolysosomal accumulation of unesterified cholesterol and glycosphingolipids such as monosialotetrahexosylganglioside (GM1) (3, 6) . To evaluate whether microglia also have these defects, we used filipin and cholera toxin staining to assess accumulation of unesterified cholesterol and GM1, respectively. Although increased over control values, GM1 levels were only significantly increased in Npc1 À/À microglia at 9 weeks of age, a time point after the observed microglial morphological and surface markers expression changes (Fig. 2B ). Unesterified cholesterol levels were markedly increased in Npc1 À/À mice at birth, prior to any detectable changes in microglia morphology or altered expression of surface makers (Fig. 2B) . Microglia from Gla Fig. S1 ). The time course differences between unesterified cholesterol and GM1 storage and morphological changes consistent with Npc1 À/À microglial activation suggest that activation is a secondary response to the microenvironment rather than a direct cell autonomous consequence of unesterified cholesterol storage since cholesterol storage occurs prior to microglial activation. Fig. S5 ). These data are consistent with data showing that Npc1 À/À monocytes also had increased phagocytosis but delayed bactericidal activity (32) . The aforementioned data show that Npc1 À/À microglia have a markedly altered activation and functional phenotype compared to Npc1
. In addition to the neurotoxic pro-inflammatory cytokines and mediators (Cybb, Il1b, Mmp12, Optn, Pde2a and Tnf), neuroprotective factors are also were quantified. (B) GM1 and unesterified cholesterol storage as mean fluorescence intensity (MFI) at birth, 3-, 7-and 9-weeks of age in microglia isolated from Npc1
(red) and Npc1 À/À (dashed blue) mice. GM1 and unesterified cholesterol accumulation was quantified by staining isolated microglial cells with Alexa488-labeled cholera toxin and filipin, respectively, n!3.
significantly upregulated (Igf1, Igf2, Igf2r, Igf2r, Igf2bp2, Tgfb2, Ttr and Vegfb) (Supplementary Material, Table S1 ). The high expression of both neurotoxic and neuroprotective genes suggests that microglia may have both detrimental and beneficial effects on NPC1 pathology. A mixed neurotoxic and neuroprotective expression profile was previously reported in ALS mouse models (15) .
À/À microglia demonstrate a shift toward glycolytic metabolism Pathway analysis of our transcriptome data identified upregulation of hypoxia-inducible factor 1-a (HIF1a) signaling and glycolysis in Npc1 À/À microglia (Table 1 ; Supplementary Material, Table S1 and Fig. S6 ). HIF1a is a regulator of immune cell metabolism and activation, driving a shift toward glycolytic metabolism in activated immune cells (33) . Increased HIF1a signaling was confirmed by western blot, which showed increased pERK1/ 2, pSAPK and IGF1 (a HIF1a target gene) in Npc1 À/À microglia ( Fig. 3A and B) . Notably, we have shown that LGALS3, a HIF1a target gene, is overexpressed in the CNS (19, 26) and can be used as a peripheral biomarker for NPC1 (34) . Increased expression of genes involved in glycolysis was functionally reflected in increased expression of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) protein ( Fig. 3A ) and an increase in glycolytic capacity in Npc1 À/À microglia (Fig. 3C ). Consistent with increased HIF1a signaling and a shift to glycolytic metabolism, we observed enhanced expression of oxidative stress related genes including peroxidases and antioxidants (Supplementary Material, Table S1 ). Additionally, western blot analysis showed increased expression of iNOS in Npc1 À/À microglia (Fig. 3A) , and we observed higher reactive oxygen species (ROS) and superoxide production in Npc1 À/À microglia, evidenced by increased 2 0 ,7 0 -dichlorofluorescin diacetate (DCFDA) and MitoSOX staining ( Fig. 3D and E, respectively). Increased expression of genes involved in the pentose phosphate shunt pathway (Table 1) is consistent with a cellular response to increase nicotinamide adenine dinucleotide phosphate (NADPH) to counter oxidative stress. To determine if our observations are relevant to patients, we measured pERK1/2, HIF1a and IGF1 protein expression in cerebellar extracts from NPC1 patients and compared them to control samples. Consistent with our mouse data, we found increased activation of the HIF1a signaling pathway in brain tissue from NPC1 patients (Fig. 3F) .
To evaluate the role of HIF1a signaling in NPC1 pathology, we inhibited HIF1a with PX-478 and evaluated the effect on microglial activation (Supplementary Material, Fig. S7 ). PX-478 treatment of Npc1 À/À mice reversed NPC1 microglia morphological changes. Npc1 À/À microglia from PX-478 treated mice became more ramified with an increase in both process length and number. Surface expression of CX 3 CR1 expression also increased toward normal and glycolysis was decreased. As expected, in vivo PX-478 treatment decreased expression of HIF1a target genes, resulting in reduced microglial ROS. However, toxic in vivo effects of PX-478 precluded evaluating the effect of HIF1a inhibition on Npc1 À/À mouse survival.
2-Hydroxypropyl-b-cyclodextrin treatment reverses microglia defects
HPbCD has been shown to decrease intracellular cholesterol and lipid accumulation, delay Purkinje neuron loss and increase lifespan in mouse (6, 8) and cat (35) NPC1 models. It also has been shown to significantly decrease disease progression in a phase 1/2a trial (13) . Consistent with prior publications, we observed a significant increase (P < 0.01) in survival of Npc1
À/À mice treated with 4000 mg.kg À1 subcutaneous HPbCD starting at either 7 or 21 days of life (134 6 33 or 91 6 7 days, respectively), compared to mice treated with carrier alone (71 6 6 days), and we also observed significant (P < 0.01) preservation of Purkinje neurons in lobules I-V (Supplementary Material, Fig. S8 ).
To determine if the efficacy of HPbCD could be partly attributed to amelioration of microglia activation, we analyzed microglia in 7-week-old animals treated for 6 weeks with HPbCD. Microglial morphology was restored to a ramified, resting appearance in HPbCD treated Npc1 À/À mice ( Fig. 4A and B;
Supplementary Material, Fig. S8 ). We also observed a decrease in CD68 following HPbCD treatment (Fig. 4C) , as previously reported (6) . HPbCD treatment also restored expression of microglia surface markers CD11b and CX 3 CR1, and significantly decreased unesterified cholesterol storage ( Fig. 4D and Supplementary Material, Fig. S8 ). There was a non-significant decrease in GM1 storage at this age. Furthermore, HPbCD reduced ROS in Npc1 À/À microglia (Fig. 4E) , and transcriptome analysis demonstrated that HPbCD treatment normalized the gene expression profile in Npc1 À/À microglia (Fig. 4F ). Pathway analysis demonstrated that neither HIF1a signaling nor glycolytic metabolism remained elevated in the HPbCD treated microglia (Table 1) . NPC1 patients are typically diagnosed after manifestation of neurological problems. Thus, to model the clinical situation, we also explored the effect of initiating HPbCD therapy at 3 weeks of age, rather than at 1 week of age (Supplementary Material, Fig. S8 ). Initiating HPbCD at 3 weeks of age was less effective with respect to survival. However, survival was still significantly increased over the vehicle control [Npc1 
Inhibiting microglia activation slows disease progression
Microglia activation is driven by several key transcription factors, particularly IRF8 (36, 37) . Irf8 is a critical regulator of microglial activation and Irf8 is not expressed in either neurons or astrocytes (36) . Irf8 mutant mice have a reduced number of microglia which do not transition from a resting state to a reactive phenotype secreting pro-inflammatory cytokines (36, 37) . Therefore, to further evaluate the role of microglia in NPC1 pathology, we compared Npc1
mice. We observed that the microglia in the Npc1
mice had significantly increased expression of CD11b and CX 3 CR1 (Fig. 5A and B) and microglial morphology approaching normal ( Fig. 5C-E) . The Npc1 À/À : Irf8 À/À mice survived on average 74.7 6 1.7 days, compared to 63.3 6 1.3 days for Npc1 (Fig. 5F ). This significant 15% increase in survival was associated with $2-week delay in the onset of neurological impairment, ascertained by rearing counts (Fig. 5G) , as well as a small delay in weight loss (Fig. 5H) . Pathological analysis at 7 weeks of age suggested delayed loss of Purkinje neurons in Npc1 (Fig. 5I) .
Collectively, these data show that targeting microglia activation can delay neuronal loss, slow disease progression and increase lifespan in NPC1 mice. Thus, targeting microglial activation may be an effective therapeutic modality for NPC1 patients.
sCD22 is a novel biomarker related to microglial activation
Transcriptome analysis revealed a significant increase in the expression of Cd22 in Npc1 À/À microglia (Fig. 6A) . In the CNS, CD22 is expressed by neurons and modulates microglia activation (38) . Increased expression of CD22 has been previously reported in aged microglia, indicating that CD22 can be found in microglia and may be a marker of microglia dysfunction (15) . Alternatively, it could indicate the presence of residual phagocytized CD22 þ neurons in the isolated microglia. Co-expression of CD22 in IBA1 positive microglia from Npc1 À/À mice was confirmed ( Fig. 6B and C) , but CD22 was not observed in Npc1
À/À microglia from HPbCD treated mice (Fig. 6B) , in which significantly less Cd22 transcripts were found (Fig. 6C) . These data suggested that CD22 might have utility as a biomarker to monitor microglial activation in patients. Indeed, we found that the mean concentration of soluble CD22 (sCD22) was significantly increased (P < 0.001) in cerebrospinal fluid (CSF) from NPC1 patients compared to sCD22 levels in CSF from age-matched controls (1.58 6 0.26 versus 1.18 6 0.04 ng.ml À1 , respectively; Fig. 6D ). The NPC1 patient CSF sCD22 levels did not correlate with total or age adjusted neurological severity scores (39); however, they decreased toward normal in response to administration of intrathecal VTS-270 (a specific formulation of HPbCD).
Comparing CSF samples prior to VTS-270 therapy to samples obtained after 18 months of therapy, we found a significant decrease (P < 0.01) in post-treatment sCD22 levels (Fig. 6E) . These data suggest that sCD22 may be a useful neuroinflammatory biomarker for monitoring therapeutic interventions.
Discussion
Neuroinflammation is a common feature of neurodegenerative diseases (15, 16) . However, the contribution of immune cells to NPC1 disease pathogenesis and progression is not clear (9, 14, 19, 20, 23, 27, 40, 41) . Previous studies have shown that Npc1 À/À microglia express increased levels of neurotoxic molecules such as TNFa (14), whereas other studies reported no measurable neurotoxic effects of Npc1 À/À microglia using co-culture experiments (40). Lopez et al. (19, 20) found that genetic deletion of C3 and CCL3, two potentially neuroinflammatory mediators with increased expression in NPC1 brain tissue, had no effect on CNS disease progression. Cologna et al. (14) reported a similar result for CCL3. In contrast, deletion of inflammatory cytokine IL-6 modestly increased lifespan, but did not prevent loss of Purkinje neurons (23) . To understand the role of microglia in NPC1 pathology we characterized Npc1 À/À microglia during NPC1 disease progression and explored the potential of therapeutically targeting neuroinflammation. In contrast to other lysosomal storage disorders such as Sandhoff (42) , mucolipidosis type IV (17) or Batten disease (16) where recruited inflammatory cells play a significant role in disease progression, we did not observe CNS infiltration of monocytes, T-cells or neutrophils in NPC1. We did observe a negligible ($2000 cells/brain) and highly variable increase in Bcells. Combined with our bone marrow transplant experiments, these data show that neuroinflammation in NPC1 is due to the microglia. The lack of a role for peripheral immune cells in NPC1 also explains why deletion of Mip1a has a significant impact on pathological progression in the Sandhoff mouse (42) but is ineffective in NPC1 (14, 19) . Although the Npc1 mutant microglia demonstrate a classical activated cellular phenotype with progressive change from a ramified appearance to a rounded amoeboid morphology, the Npc1
À/À microglia demonstrate a non-conventional polarization with decreased expression of lineage makers (CD11b and CX 3 CR1), unchanged expression of activation markers (MHCII, F4/80, CD86) and mixed expression of neurotoxic and neuroprotective genes. Morphological changes and altered expression of CD11b and CX 3 CR1 become apparent after 3 weeks of age. However, significant storage of unesterified cholesterol is present at birth, prior to microglial activation. These data suggest that accumulation of unesterified cholesterol is not sufficient to trigger microglial activation and suggest that other activating signals, such as neuronal cell death, are necessary to induce neuroinflammation. 
and Npc1 Consistent with this hypothesis, we and others have observed microglial activation at sites of neuronal cell death (8, 43) . The mixed expression of both neurotoxic and neuroprotective genes suggests that microglia may have both beneficial and detrimental roles in NPC1 pathology. This would be consistent with the concept that neuroinflammation may be a two-edged sword in neurodegenerative diseases (15, 24) and conflicting contribution to pathology could potentially limit the efficacy of therapies designed to directly modulate microglial activation. Performing transcriptome analysis on purified microglia allowed us to identify microglial functional defects in a more specific and comprehensive way than previous approaches using cultured microglia or complete brain tissue (19, 26) . We identified a shift toward glycolytic metabolism in Npc1 À/À microglia mediated by HIF1a signaling. This glycolytic metabolic signature has also been reported in tissues from other neurodegenerative diseases and following in vitro activation of microglial cells (25, 44) , indicating that this glycolytic shift may be a general marker of microglia activation, as previously shown for other myeloid cells (33) . We could confirm that HIF1a signaling plays a functional role in Npc1 À/À microglial activation by inhibiting HIF1a with PX-478. Unfortunately, toxic effects of general HIF1a inhibition lead to significant weight loss (45) and blocking of pro-survival signals in neurons (46) , preclude evaluating the potential benefit of HIF1a inhibition on neurological function and survival in the Npc1 mutant mouse model.
HPbCD has previously been shown to delay onset of neurological manifestations and death in NPC1 animals (6, 8, 35) , and slow disease progression in a phase 1/2a trial (13) . We thus explored the effect of HPbCD treatment on microglial activation in Npc1 mutant mice. HPbCD decreased microglia activation as evidenced by changes in morphology, normalization of immune marker expression, decreased ROS and normalization of gene expression. Consistent with prior studies, early treatment with HPbCD initiated on DOL 7 is more efficacious than therapy initiated after weaning. This is true with respect to survival and markers of microglial activation. These data suggest that therapies directed against neuroinflammation need to be initiated early and perhaps prior to neurological manifestations being apparent.
Although microglial cholesterol storage and activation are decreased by treatment with HPbCD, these experiments do not distinguish between a primary effect of HPbCD on Npc1 À/À microglia and a secondary effect on microglial activation due to delayed neuronal loss. To gain insight into the direct contribution of microglia activation on NPC1 neuropathology, we studied Npc1 À/À : Irf8 À/À mice. Loss of IRF8 function in Irf8 mutant mice results in a significant decrease in number of microglia in the CNS and impaired activation of remaining microglia (36) . We found that Npc1 Irf8 expression is limited to microglia in the CNS, this suggests a direct role of microglia in NPC1 disease progression that may be amendable to therapeutic intervention. Our current data do not exclude either a primary or secondary contribution of astrocytes to NPC1 neuroinfammatory pathology. Therapeutic interventions that broadly reduce inflammation in NPC1 have shown mixed results. Administration of minocycline (27) did not affect disease progression whereas ibuprofen (22) and necrostatin-1 (43) significantly increases the lifespan of Npc1 À/À mice. These mixed results may be consistent with our transcriptome analysis indicated that Npc1 À/À microglia are neither strongly proinflammatory (neurotoxic) or anti-inflammatory (neuroprotective). Additional work will be necessary to determine the pathways controlling microglial activation and polarization in NPC1 to specifically target the deleterious aspects of neuroinflammation. Recent advances in single cell RNA-seq have demonstrated the existence of a microglia subpopulation associated with neurodegenerative disease with a similar gene expression profile as observed in Npc1 À/À microglia (47) . Disease associated microglia markers Axl, Apoe, Cd9, Cst7, Ctsb, Ctsl, Clec7a, Csf1, Ctsd, Itgax, Ldl, Timp2, Trem2 and Tyrobp are decreased in VTS-270 treated animals, supporting the efficacy of the drug preventing the change in microglia properties and further application in neurodegenerative diseases. Single cell RNA-seq in vehicle and treated animals may provide supporting additional evidence of the treatment efficacy in vivo.
Biomarkers are tools which can provide pathological insight into potential therapies. We identified sCD22 as a biomarker that may be useful to monitor neuroinflammation in NPC1. Although there is some overlap with our control population, this biomarker is likely to be useful in the majority of cases. CD22 is normally expressed by neurons and functions to prevent microglial activation (38) . Thus, increased CD22 mRNA in Npc1 À/À microglia may be an indicator of increased phagocytosis of neurons. Consistent with our observations of increased activation and phagocytic capacity in Npc1 À/À microglia, we observed significantly elevated sCD22 levels in CSF from NPC1 patients. Notably, we also found that CSF levels of sCD22 decreased significantly in NPC1 patients treated with intrathecal VTS-270. These data, combined with our prior data (13) , suggest that intrathecal VTS-270 therapy reduces neuroinflammation in parallel with a reduction in CSF markers of neuronal damage and a decrease in the rate of neurological disease progression. The data presented in this paper demonstrate a mixed pattern of microglial activation in NPC1, show that microglial activation contributes to neurological disease progression, and suggest that its modulation may have beneficial effects as part of a combined therapy to treat NPC1. Furthermore, we could translate this work to patients by identifying a novel biomarker, sCD22, that may provide useful in monitoring the response of neuroinflammation to therapeutic interventions.
Materials and Methods
Antibodies and reagents
Unless otherwise specified, antibodies and reagents were obtained from Thermo Fisher Scientific, Waltham, USA.
Mouse models and drug treatment
All mouse experiments were approved by the NICHD Animal Care and Use Committee. To account for potential variability due to mouse background, all experiments were conducted using control mice obtained from the same crosses used to obtain mutant mice. BALB/cNctr-Npc1 mice were euthanized at a humane end-point (weight loss >30% of peak weight, hunched posture and reluctance to move and inability to remain upright when moving forward). Loss of motor function was ascertained by rearing counts as previously described (9) . Briefly, mice were acclimatized to a clean cage for 30 min and then observed for a period of 5 min. Spontaneous rearing, with or without support of the cage wall was recorded manually.
Human participants
NPC1 patients were enrolled in a longitudinal Natural History protocol (NCT00344331) or a phase 1/2a trial of intrathecal VTS-270 (NCT01747135) at the NIH Clinical Center. These clinical protocols were approved by the NICHD Institutional Review Board. Informed consent was obtained from guardians or participants. Assent was obtained when applicable. CSF was collected by lumbar puncture and stored at À80 C. Control CSF was obtained from 30 gender and age-matched patients who were undergoing cerebrospinal collection for another clinical indication. Four control patients were febrile (>38.5 C) at the time of CSF collection, but none had elevated white blood cell count or positive cultures. Age of control subjects ranged from 2 weeks to 20 years at the time of CSF collection. Human post-mortem tissue was obtained from the NICHD Blood and Tissue Bank (http:// medschool.umaryland.edu/btbank/) and processed for western blot analysis as previously described (14) .
Generation of bone marrow chimeras
Femurs and tibias from donor 6-to 8-week-old Npc1 þ/þ and Npc1 À/À mice were removed aseptically and bone marrow flushed out using ice-cold PBS (Sigma Aldrich, St Louis, USA) supplemented with 2 mM ethylenediaminetetraacetic acid (EDTA) (Sigma). Bone marrow cells were counted using Trypan Blue exclusion, and 3-5Â10 6 cells injected intravenously into 3-to 4-week-old recipient Npc1 þ/þ and Npc1 À/À mice. Recipient mice were first irradiated with two doses of 400 RAD, given 4 h apart. Bone marrow injections were performed 24 h following the second irradiation. Mice were given trimethoprim/sulfamethoxazole in the drinking water for the first 4 weeks of reconstitution and then switched to antibiotic-free water. Motor function and weight were assessed twice a week until sacrifice of the animal, 10 weeks post-irradiation or until they reach disease end-point and were sacrificed.
Microglia isolation, FACS sorting and analysis
Microglia were isolated and analyzed as previously describe with minor modifications (48) . Mice were sacrificed using CO 2, before cardiac perfusion with 25 ml of ice-cold PBS. Brain were removed without the spinal cord and suspended and triturated in ice-cold FACS buffer [PBS containing 0.5% BSA (Sigma)] using syringe plunger. Microglia were separated from neurons using a discontinuous Percoll gradient 30-70% (GE healthcare, Chicago, USA BD wash buffer. After three washes with FACS buffer, stained cells were fixed using 2% paraformaldehyde prior analysis. Stained sample were analyzed using a LSR Fortessa (BD) and the data analyzed using FlowJo software (TreeStar, Ashland, USA). Only single cells were analyzed, and cell numbers were quantified using PE-conjugated fluorescent counting beads (Spherotech, Lake Forest, USA). The FACS strategy is presented in Supplementary Material, Figure S3 . Quality of the cell isolation method was evaluated by Giemsa (Sigma) staining or IBA1 (Wako, Richmond, USA) staining on cells isolated and cytospin on gelatin coated slide (SouthernBiotech, Birmingham, USA). Between 92 and 97% of the sorted cells were IBA1 positive by manual counting of the cells after cytospin under epifluorescence microscope Zeiss Axioskope (Carl Zeiss, Oberkochen, Germany).
RNA extraction, RNA-seq and RT-PCR
Triple positive (CX 3 CR1, CD45 and CD11b) live cell was isolate using FACS Aria 3 (BD). Cells were collected in 200 ll of FACS buffer, spun at 1000 g for 10 min at 4 C, cell pellet was frozen in 700 ll TRIzol. Reagent were allowed to defrost at room temperature, 200 ll chloroform (Sigma) was added and mix for 15 s. Aqueous phase after 15min centrifugation at 12 000g at 4 C was mixed with anhydrous ethanol. Solution was loaded onto RNeasy micro plus column (Qiagen, Hilden, Germany) and then total RNA was purified according to manufacturer instruction. Elution product concentration and quality was evaluated using qubit and PicoChip Bioanalyzer. RNA-seq libraries were constructed using SMARTer Stranded Total RNA-Seq Kit-Pico Input Mammalian (Takara Bio USA, Inc. Mountain View, USA). In brief, 2 ng total RNA from each sample was fragmented, reverse-transcribed to cDNA, and then adapters for Illumina sequencing (Illumina, San Diego, USA) (with specific barcode) were added through polymerase chain reaction (PCR) using only a limited number of cycles. The PCR products are purified, and then ribosomal cDNA was depleted using probes specific to mammalian rRNA. The cDNA fragments were further amplified with primers universal to all libraries. These libraries were pooled together and sequenced using Illumina HiSeq 2500 to generate $40 million 2Â100 paired-end reads for each sample. The raw data were demultiplexed and analyzed further. Sequence alignment was performed using RNA-STAR (49). Quantitation with subread featureCounts (50) and comparisons of expression with DESeq2 (51) . RNAseq data are available from the NCBI, NIH Gene Expression Omnibus (GEO) database (GSE109083).
The following TaqMan assays were used to assess the relative expression level of: Lgals3 (Mm00802901_m1), Gapdh (Mm03302 249_g1) Igf1 (Mm00439560_m1) Hprt (Mm03024075_m1) on cDNA as previously describe (34) .
Measurement of reactive oxidative stress
DCFDA (Sigma-Aldrich, St. Louis, USA) or MitoSOX red staining was performed according to manufacturer instruction. In Brief, 10 000 cells were seeded per well just after isolation and allowed for 2 h to attach on the bottom of fluorescence 96-well plate wells (Sigma), cells were washed twice with 100 ll PBS and stained for 30 min with1 ll of 2 mM DCFDA or 0.5 ll of MitoSOX solution were added per well and 96-well plates were red on and automated plate reader (485 nm; 528 nm).
Measurement of energy metabolism
Real-time measurements extracellular acidification rates, a measure of lactate production, were performed on an XF96e Seahorse extracellular flux analyzer (Agilent Technology, Savage, USA) according to manufacturers' instructions. Measurement were performed on 10 000 cells per wells.
Western blot and ELISA
Total proteins were extracted from isolated microglia, human cerebellar tissue and mouse tissues using radioimmunoprecipitation assay (RIPA) buffer (50 mM Tris-HCl, pH7.4, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 150 mM NaCl, 2 nM EDTA, 40 mM NaF, 0.2 mM Na 3 VO 4 ) with complete protease inhibitor cocktail (Roche, Basel, Switzerland). Protein amounts were determined using the DC assay (Bio-Rad Laboratories, Hercules, USA). Protein lysates (typically 5-20 lg) were loaded onto a 4-12% gradient NuPAGE Gel, and electrophoresis was carried out at a constant 120 V. Protein transfer was performed using the iBLOT2 dry transfer setup (25 V, 12 min). Following transfer, nitrocellulose membranes were incubated in a 2% BSA and PBS 0.1% Tween 20 blocking buffer for 1 h at room temperature, followed by incubation with the primary antibody at 4 C overnight.
After the initial incubation, the membrane was rinsed and 
Immunofluorescence
Brain cerebellar tissue was processed as described. Mice were euthanized weeks by CO 2 asphyxiation and transcardialy perfused with ice-cold 4% paraformaldehyde in PBS, pH 7.4. The brains were post-fixed in 4% paraformaldehyde solution for 24 h and then cryoprotected in 30% sucrose (Sigma). Cerebellar tissues were cryostat-sectioned parasagittally (20 lm) and floating sections were collected in PBS with 0.25% Triton X-100 (Sigma). Sections were incubated overnight at 4 C with mouse anticalbindin (1/1000, Sigma), rabbit-anti IBA1 (1/200, Wako), rat anti-CD11b (1/100, Sigma), rat-anti CD68-PE (1/100, FA-11, Biolegend), Hoechst3342 (1/5000, and rat anti CD22 (1/500, OX97, Biolegend). Detected using Dy-Ligh-488 or Dy-Light-594 goat anti-mouse IgG (Vector, Burlingame, USA). Images were taken using a Zeiss Axio Observer Z1 microscope fitted with an automated scanning stage, Colibri II LED illumination and Zeiss ZEN2 software using a high-res AxioCam MRm camera and a 20 Â objective. Each fluorophore channel was pseudo-colored in ZEN2, exported as JPEG, and analyzed using ImageJ (52) . Purkinje cells were counted by measuring the number of calbindin positive Purkinje cell bodies with the recognizable dendritic tree or axonal projection still remaining within a given cerebellar lobule. The data were expressed as the number of Purkinje cells per 100 mm of Purkinje cell layer: granule cell layer interface. The entire lobule was counted per section, with 3 sections counted per brain.
Assessment of blood-brain-barrier integrity
A 2% solution of Evans Blue (Sigma) in normal saline (4 ml.kg À1 of body weight) was injected intraperitoneally. Sample where analyzed as detailed previously (53) .
Phagocytosis
Bacterial uptake and intracellular survival and replication were tested with the non-pathogenic Escherichia coli DH10b. Bacteria were freshly grown in Luria broth media at 37 C and used at exponential growth phase. Total of 10 000 FACS-sorted live microglia in 96-well flat bottom plates were infected at a multiplicity of infection of 10 bacteria per cell. At 1 h post-infection, new complete medium supplemented with 100 mg/ml gentamicin was added. At 3, 7, 15 and 23 h post-infection the cells were washed and lysed in 1% Triton X-100 in deionized water to determine the number of colony-forming units (CFU) recovered from the lysed microglia on Luria broth agar plates.
Statistical analysis
Results are presented as mean 6 SEM unless specified. MannWhitney U-test was used to compare between two groups. Differences were considered significant if the nominal P-value was *P < 0.05, **P < 0.01 and ***P < 0.001. Statistical calculations were performed using GraphPad Prism software (San Diego, USA). Heatmap and clustering were performed with Morpheus https://software.broadinstitute.org/morpheus/.
Pathway analysis
Pathway analysis were performed using: WebGSALT (54), g:Profiler (55), STRING (56) and ConsensusPathDB (57) . Default settings were used for all four web resources. A significant enrichment for a pathway was set with P < 0.05.
Supplementary Material
Supplementary Material is available at HMG online.
